Clinical Trials & Research
Search Clinical Trials
|Title||Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor|
|Description||The purpose of this phase 2 trial is tostudy the side effects of giving temsirolimus together with bevacizumab and to see how well it works in treating patients with locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor.|
Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.
Giving temsirolimus together with bevacizumab may kill more tumor cells.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years and older
* Patient has histologically or cytologically confirmed diagnosis of 1 of the following:
* Patient has Endometrial cancer (endometrioid only)
* Patient is not on an active liver transplant list and considered likely to receive a liver transplant within the next 6 months
* Patient has no significant traumatic injury within the past 4 weeks
* Patient has no serious non-healing wound, ulcer, or bone fracture
|Principal Investigator||Andreas Kaubisch, MD|
|Contact Name||Yoko Eng, NP|
|Current Trial Type||Interventional|
|Montefiore Clinical Trial||No|
|CHAM Clinical Trial||No|